Search
Patexia Research
Case number 2023-1247

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. > Documents

Date Field Doc. No.Description (Pages)
Aug 23, 2023 66 Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [945145] [MVH] [Entered: 08/23/2023 08:59 AM] (1)
Aug 16, 2023 65 ORDER filed denying [57] petition for panel rehearing and rehearing en banc filed by Vanda Pharmaceuticals Inc. By: Per Curiam. Service as of this date by the Clerk of Court. [943530] [MVH] [Entered: 08/16/2023 12:13 PM] (2)
Aug 11, 2023 64 ORDER filed denying [60] motion to file a response/reply filed by Vanda Pharmaceuticals Inc. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [942499] [MVH] [Entered: 08/11/2023 04:52 PM] (2)
Aug 6, 2023 63 REPLY of Appellant Vanda Pharmaceuticals Inc. to response [62]. Service: 08/06/2023 by email. [940909] [23-1247] [Paul Hughes] [Entered: 08/06/2023 10:10 PM] (6)
Aug 4, 2023 62 RESPONSE of Appellees Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp. to Doc No. [60]. Service: 08/04/2023 by email. [940880] [23-1247] [John Rozendaal] [Entered: 08/04/2023 06:28 PM] (16)
Aug 4, 2023 61 Amended Entry of Appearance for John Christopher Rozendaal; Byron L. Pickard; Deirdre M. Wells; William H. Milliken; Sasha S. Rao as counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 08/04/2023 by email. [940878] [23-1247] [John Rozendaal] [Entered: 08/04/2023 06:21 PM] (2)
Aug 3, 2023 60 MOTION of Appellant Vanda Pharmaceuticals Inc. for leave to file a response/reply to Doc. No. [59]. Service: 08/03/2023 by email. [940607] [23-1247] [Paul Hughes] [Entered: 08/03/2023 06:45 PM] (23)
Jul 31, 2023 59 RESPONSE of Appellees Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp. to Doc No. [57], [57]. Service: 07/31/2023 by email. [939645] [23-1247] [John Rozendaal] [Entered: 07/31/2023 04:49 PM] (24)
Jul 18, 2023 58 The court invites a response from Appellees Apotex Corp., Apotex Inc. and Teva Pharmaceuticals USA, Inc. to the petition [57]. Response due 08/01/2023. Service as of this date by the Clerk of Court. [936864] [MVH] [Entered: 07/18/2023 10:25 AM] (1)
Jun 20, 2023 57 Petition for panel rehearing, for en banc rehearing filed by Appellant Vanda Pharmaceuticals Inc.. Service: 06/20/2023 by email. [931024] [23-1247] [Paul Hughes] [Entered: 06/20/2023 01:12 PM] (44)
Jun 16, 2023 56 Entry of Appearance for Sarah P. Hogarth; Christopher M. Bruno; April E. Weisbruch as counsel for Appellant Vanda Pharmaceuticals Inc.. Service: 06/15/2023 by email. [930773] [MVH] [Entered: 06/16/2023 05:10 PM] (2)
Jun 16, 2023 55 ORDER filed granting motion leave to appear as counsel [54] filed by Appellant Vanda Pharmaceuticals Inc. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [930772] [MVH] [Entered: 06/16/2023 05:09 PM] (2)
Jun 15, 2023 54 MOTION of Appellant Vanda Pharmaceuticals Inc. for leave to file entry of appearance for Paul W. Hughes; Sarah P. Hogarth; Christopher M. Bruno; April E. Weisbruch. Service: 06/15/2023 by email. [930357] [23-1247] [Paul Hughes] [Entered: 06/15/2023 01:49 PM] (9)
Jun 15, 2023 53 Amended Entry of Appearance for Nicholas P. Groombridge; Eric Alan Stone; Josephine Young; Daniel Klein; Michael F. Milea; Jennifer Rea Deneault as counsel for Appellant Vanda Pharmaceuticals Inc.. Service: 06/15/2023 by email. [930313] [23-1247] [Michael Milea] [Entered: 06/15/2023 12:06 PM] (2)
Jun 12, 2023 52 NOTICE OF NON-COMPLIANCE: The submissions of Appellant Vanda Pharmaceuticals Inc., Entry of Appearance; Petition for Rehearing or Rehearing En Banc [50], [51],[51], are not in compliance with the rules of this court (see attached). Compliant documents due on 06/20/2023. Service as of this date by the Clerk of Court. [929224] [MVH] [Entered: 06/12/2023 11:22 AM] (2)
Jun 9, 2023 51 Petition for panel rehearing, for en banc rehearing filed by Appellant Vanda Pharmaceuticals Inc.. Service: 06/09/2023 by email. [929114] [23-1247]. This document is non-compliant. See Doc. No. [52] [Paul Hughes] [Entered: 06/09/2023 07:34 PM] (44)
Jun 9, 2023 50 Entry of Appearance for Paul W. Hughes; Sarah P. Hogarth; Christopher M. Bruno; April E. Weisbruch as counsel for Appellant Vanda Pharmaceuticals Inc.. Service: 06/09/2023 by email. [929113] [23-1247]. This document is non-compliant. See Doc. No. [52] [Paul Hughes] [Entered: 06/09/2023 07:31 PM] (2)
May 14, 2023 0 VANDA PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. [OPINION] [nonprecedential] (0)
May 10, 2023 49 JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [922385] [MVH] [Entered: 05/10/2023 10:22 AM] (1)
May 10, 2023 48 OPINION filed for the court by Dyk, Circuit Judge; Bryson, Circuit Judge and Prost, Circuit Judge. Nonprecedential Opinion. Service as of this date by the Clerk of Court. [922383] [MVH] [Entered: 05/10/2023 10:21 AM] (17)
Mar 14, 2023 47 Submitted after ORAL ARGUMENT to Panel: Dyk, Circuit Judge; Bryson, Circuit Judge and Prost, Circuit Judge.Arguing counsel: Nicholas P. Groombridge for Vanda Pharmaceuticals Inc., Aaron S. Lukas for Apotex Inc. and Apotex Corp. and John Christopher Rozendaal for Teva Pharmaceuticals USA, Inc.Oral Argument Audio available here. [909705] [MJL] [Entered: 03/14/2023 11:13 AM] (0)
Mar 13, 2023 46 6 paper copies of Doc. Nos. [43], [44] received from Vanda Pharmaceuticals Inc. [909632] [MJL] [Entered: 03/13/2023 05:09 PM] (0)
Mar 10, 2023 45 REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.3 to promptly submit an amended Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [909174] [MMA] [Entered: 03/10/2023 12:52 PM] (0)
Mar 9, 2023 44 MODIFIED ENTRY: APPENDIX FILED by Appellant Vanda Pharmaceuticals Inc. Service: 03/09/2023 by email. [908974]--[Edited 03/10/2023 by MMA - Reason: compliance review complete] The paper copies of the appendix must be submitted on or before 03/13/2023. [Nicholas Groombridge] [Entered: 03/09/2023 04:24 PM] (1475)
Mar 9, 2023 43 MODIFIED ENTRY: REPLY BRIEF FILED by Appellant Vanda Pharmaceuticals Inc. Service: 03/09/2023 by email. [908854]--[Edited 03/10/2023 by MMA - Reason: compliance review complete] The paper copies of this brief must be submitted on or before 03/13/2023. [Nicholas Groombridge] [Entered: 03/09/2023 02:22 PM] (42)
Mar 6, 2023 42 6 paper copies of Doc. No. [41] received from Appellees Apotex Corp., Apotex Inc. and Teva Pharmaceuticals USA, Inc. [907954] [MJL] [Entered: 03/06/2023 02:20 PM] (0)
Feb 27, 2023 41 MODIFIED ENTRY: RESPONSE BRIEF FILED by Appellees Apotex Corp., Apotex Inc. and Teva Pharmaceuticals USA, Inc. Service: 02/27/2023 by email. [906579]--[Edited 03/02/2023 by MMA - Reason: compliance review complete] The paper copies of this brief must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [John Rozendaal] [Entered: 02/27/2023 03:41 PM] (82)
Feb 14, 2023 40 Amended Response to notice of oral argument from Appellees Apotex Corp. and Apotex Inc.. Service: 02/14/2023 by email. [904213] [23-1247] [Aaron Lukas] [Entered: 02/14/2023 04:23 PM] (1)
Feb 8, 2023 39 CLERK'S OFFICE QUALITY CONTROL MESSAGE: The responses to notice of oral argument (RNOA) filed for John C. Rozendaal [37] and Aaron S. Lukas [38] idicate that two counsel intend to present oral argument on behalf of Teva Pharmaceuticals USA, Inc. Pursuant to FCR 34(e)(2), only one counsel may argue per party. CORRECTION: No later than 02/15/2023, Apotex and Teva shall file amended RNOAs that comply with the limitations of FCR 34(e)(2) or a motion to waive requirements. [902985] [MJL] [Entered: 02/08/2023 05:02 PM] (0)
Feb 6, 2023 38 Response to notice of oral argument from Appellees Apotex Corp. and Apotex Inc.. Service: 02/06/2023 by email. [902206] [23-1247] [Aaron Lukas] [Entered: 02/06/2023 03:32 PM] (1)
Feb 6, 2023 37 Response to notice of oral argument from Appellee Teva Pharmaceuticals USA, Inc.. Service: 02/06/2023 by email. [902196] [23-1247] [John Rozendaal] [Entered: 02/06/2023 03:23 PM] (1)
Feb 6, 2023 36 Response to notice of oral argument from Appellant Vanda Pharmaceuticals Inc.. Service: 02/06/2023 by email. [902158] [23-1247] [Nicholas Groombridge] [Entered: 02/06/2023 02:25 PM] (1)
Jan 26, 2023 35 6 paper copies of Doc. No. [34] received from Appellant Vanda Pharmaceuticals Inc.. [900005] [VDW] [Entered: 01/26/2023 04:31 PM] (0)
Jan 23, 2023 33 Amended Entry of Appearance for Nicholas Groombridge; Eric Alan Stone; Josephine Young; Daniel J. Klein; Michael Milea; Jennifer Rea Deneault as counsel for Appellant Vanda Pharmaceuticals Inc.. Service: 01/23/2023 by email. [898843] [23-1247] [Nicholas Groombridge] [Entered: 01/23/2023 06:10 PM] (2)
Jan 23, 2023 34 MODIFIED ENTRY: OPENING BRIEF FILED by Appellant Vanda Pharmaceuticals Inc. Service: 01/23/2023 by email. [898844]--[Edited 01/25/2023 by MMA - Reason: compliance review complete] The paper copies of this brief must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [Nicholas Groombridge] [Entered: 01/23/2023 06:12 PM] (278)
Jan 23, 2023 32 NOTICE OF ORAL ARGUMENT. Panel: 2303K. Case scheduled March 14, 2023. Response to Notice of Oral Argument due: 02/06/2023. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [898730] [MVH] [Entered: 01/23/2023 03:33 PM] (2)
Jan 6, 2023 31 Clerk's Note to the File: This appeal will be scheduled for oral argument at 10:00 a.m. on 03/14/2023 in Washington, DC. A formal calendar notice will follow in due course. [895205] [MJL] [Entered: 01/06/2023 01:31 PM] (0)
Dec 29, 2022 30 Docketing Statement for the Appellant Vanda Pharmaceuticals Inc.. Service: 12/29/2022 by email. [893727] [23-1247] [Daniel Klein] [Entered: 12/29/2022 09:56 PM] (4)
Dec 29, 2022 29 Docketing Statement for the Appellees Apotex Corp. and Apotex Inc.. Service: 12/29/2022 by email. [893724] [23-1247] [William Coblentz] [Entered: 12/29/2022 07:48 PM] (5)
Dec 29, 2022 28 Docketing Statement for the Appellee Teva Pharmaceuticals USA, Inc.. Service: 12/29/2022 by email. [893715] [23-1247] [John Rozendaal] [Entered: 12/29/2022 05:44 PM] (5)
Dec 28, 2022 27 ORDER filed denying [2] the motion to enjoin, and this court's temporary injunction is now lifted.; granting motion to expedite [24] filed by Appellant Vanda Pharmaceuticals Inc.; Vanda's opening brief is due no later than January 23, 2023; the appellees' response briefs are due no later than February 27, 2023; and Vanda's reply brief and the joint appendix are due no later than March 9, 2023. Oral argument will be addressed by separate order. (Per Curiam). Service as of this date by the Clerk of Court. [893327] [LMS] [Entered: 12/28/2022 01:00 PM] (2)
Dec 28, 2022 26 REPLY of Appellant Vanda Pharmaceuticals Inc. to response [25]. Service: 12/28/2022 by email. [893211] [23-1247] [Nicholas Groombridge] [Entered: 12/28/2022 08:47 AM] (84)
Dec 23, 2022 25 RESPONSE of Appellees Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp. to Doc No. [2]. Service: 12/23/2022 by email. [892835] [23-1247] [John Rozendaal] [Entered: 12/23/2022 04:58 PM] (103)
Dec 23, 2022 24 MOTION of Appellant Vanda Pharmaceuticals Inc. to expedite briefing schedule. Service: 12/23/2022 by email. [892663] [23-1247] [Daniel Klein] [Entered: 12/23/2022 11:45 AM] (13)
Dec 22, 2022 23 ORDER filed The motion for reconsideration [9] is granted in part and denied in part. The temporary injunction issued by this court on December 16, 2022, will remain in effect until the court enters an order on Vanda Pharmaceuticals Inc'�??s motion for a stay of the district court�??'s order pending appeal. However, the schedule for the remaining briefs on the motion for a stay will be expedited. (see order for further details) (Per Curiam). Service as of this date by the Clerk of Court. [892454] [NL] [Entered: 12/22/2022 12:27 PM] (2)
Dec 22, 2022 22 REPLY of Appellee Teva Pharmaceuticals USA, Inc. to response [19], response [16]. Service: 12/22/2022 by email. [892389] [23-1247] [John Rozendaal] [Entered: 12/22/2022 10:48 AM] (20)
Dec 21, 2022 21 Transcript Purchase Order Form for the Appellant Vanda Pharmaceuticals Inc. indicating that a request is made to the reporter for a transcript. Service: 12/21/2022 by email. [892110] [23-1247] [Daniel Klein] [Entered: 12/21/2022 01:43 PM] (1)
Dec 21, 2022 20 Confidential APPELLANTS OPPOSITION TO APPELLEES EMERGENCY MOTION FOR REVIEW, RECONSIDERATION, OR MODIFICATION OF TEMPORARY INJUNCTION filed by Appellant Vanda Pharmaceuticals Inc. corresponding to Doc. No. [19]. Service: 12/21/2022 by email. [892075] [23-1247] [Nicholas Groombridge] [Entered: 12/21/2022 11:58 AM] (0)
Dec 21, 2022 19 RESPONSE of Appellant Vanda Pharmaceuticals Inc. to Doc No. [9]. Service: 12/21/2022 by email. [892069] [23-1247] [Nicholas Groombridge] [Entered: 12/21/2022 11:47 AM] (96)
Dec 21, 2022 18 Confidential Appellees Apotex Inc. and Apotex Corp.'s Opposition to Appellee Teva Pharmaceuticals USA, Inc.'s Emergency Motion for Review, Reconsideration, or Modification of Temporary Injunction (With Confidential Exhibit A) filed by Appellees Apotex Corp. and Apotex Inc. corresponding to Doc. No. [16]. Service: 12/21/2022 by email. [892064] [23-1247] [William Coblentz] [Entered: 12/21/2022 11:42 AM] (0)
Dec 21, 2022 17 Entry of Appearance for Nicholas Groombridge, Eric Alan Stone, Josephine Young, Daniel J. Klein, Michael Milea, Jennifer Rea Deneault as counsel for Appellant Vanda Pharmaceuticals Inc.. Service: 12/21/2022 by email. [892063] [23-1247] [Nicholas Groombridge] [Entered: 12/21/2022 11:41 AM] (2)
Dec 21, 2022 16 RESPONSE of Appellees Apotex Corp. and Apotex Inc. to Doc No. [9]. Service: 12/21/2022 by email. [892062] [23-1247] [William Coblentz] [Entered: 12/21/2022 11:37 AM] (11)
Dec 21, 2022 15 Certificate of Interest for Appellees Apotex Corp. and Apotex Inc.. Service: 12/21/2022 by email. [892061] [23-1247] [William Coblentz] [Entered: 12/21/2022 11:34 AM] (3)
Dec 21, 2022 14 Entry of Appearance for William Blake Coblentz; Aaron S. Lukas; Keri L. Schaubert as counsel for Appellees Apotex Corp. and Apotex Inc.. Service: 12/21/2022 by email. [892060] [23-1247] [William Coblentz] [Entered: 12/21/2022 11:32 AM] (2)
Dec 20, 2022 13 Corrected Entry of Appearance for Nicholas Groombridge; Eric Alan Stone; Josephine Young; Daniel J. Klein; Jennifer Rea Deneault; Michael F. Milea as counsel for Appellant Vanda Pharmaceuticals Inc.. Service: 12/20/2022 by email. [891861] [23-1247] [Daniel Klein] [Entered: 12/20/2022 02:57 PM] (2)
Dec 19, 2022 12 ORDER filed Responses to ECF Nos. [9] and [10] are due no later than Wednesday, December 21, 2022, at noon Eastern time. Any reply in support of ECF Nos. [9] and [10] is due no later than Thursday, December 22, 2022, at 3:00pm Eastern time. (Per Curiam). Service as of this date by the Clerk of Court. [891626] [NL] [Entered: 12/19/2022 05:54 PM] (2)
Dec 19, 2022 11 NOTICE OF NON-COMPLIANCE: The submission of Appellant Vanda Pharmaceuticals Inc., Entry of Appearance [4], is not in compliance with the rules of this court (see attached). Compliant document due on 12/27/2022. Service as of this date by the Clerk of Court. [891617] [MMA] [Entered: 12/19/2022 05:29 PM] (1)
Dec 19, 2022 10 Confidential MOTION of Appellee Teva Pharmaceuticals USA, Inc. to reconsider Doc. No. [6] filed by Appellee Teva Pharmaceuticals USA, Inc. corresponding to Doc. No. [9]. Service: 12/19/2022 by email. [891511] [23-1247]--[Edited 12/19/2022 by MMA to revise docket text] [John Rozendaal] [Entered: 12/19/2022 02:49 PM] (0)
Dec 19, 2022 9 MOTION of Appellee Teva Pharmaceuticals USA, Inc. to reconsider Doc. No. [6]. Service: 12/19/2022 by email. [891509]--[Edited 12/19/2022 by MMA - Reason: to correct filing event] [John Rozendaal] [Entered: 12/19/2022 02:44 PM] (42)
Dec 19, 2022 8 Certificate of Interest for Appellee Teva Pharmaceuticals USA, Inc.. Service: 12/19/2022 by email. [891346] [23-1247] [John Rozendaal] [Entered: 12/19/2022 10:10 AM] (4)
Dec 19, 2022 7 Entry of Appearance for John Christopher Rozendaal; Deirdre M. Wells; Byron L. Pickard; William H. Milliken; Sasha S. Rao as counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 12/19/2022 by email. [891345] [23-1247] [John Rozendaal] [Entered: 12/19/2022 10:07 AM] (2)
Dec 16, 2022 6 ORDER filed directing appellees to respond to Vanda's motion at ECF No. 2 [2] no later than December 29, 2022. Any reply is due no later than January 6, 2023.; granting ECF No. 3 [3] to the extent that appellees are temporarily enjoined from commercial marketing and sale of their tasimelteon products while the court considers ECF No. 2.; (Per Curiam). Service as of this date by the Clerk of Court. [891127] [LMS] [Entered: 12/16/2022 12:55 PM] (2)
Dec 15, 2022 5 Certificate of Interest for Appellant Vanda Pharmaceuticals Inc.. Service: 12/15/2022 by email. [890883] [23-1247] [Daniel Klein] [Entered: 12/15/2022 12:26 PM] (3)
Dec 15, 2022 4 Entry of appearance for Nicholas Groombridge; Eric Alan Stone; Josephine Young; Daniel J. Klein; Jennifer Rea Deneault; Michael F. Milea as counsel for Appellant Vanda Pharmaceuticals Inc.. Service: 12/15/2022 by email. [890868] [23-1247] [Daniel Klein] [Entered: 12/15/2022 11:48 AM] (2)
Dec 15, 2022 3 MOTION of Appellant Vanda Pharmaceuticals Inc. to enjoin generic launch pending this court's ruling on Appellant's Rule 8 motion [2]. Service: 12/14/2022 by email. [890810] [MMA] [Entered: 12/15/2022 10:19 AM] (43)
Dec 15, 2022 2 MOTION of Appellant Vanda Pharmaceuticals Inc. for temporary injunction. Service: 12/14/2022 by email. [890804] [MMA] [Entered: 12/15/2022 10:15 AM] (470)
Dec 15, 2022 1 Appeal docketed. Received: 12/14/2022. [890798]Entry of Appearance due 12/29/2022. Certificate of Interest is due on 12/29/2022. Docketing Statement due 12/29/2022. Appellant's brief is due 02/13/2023. [MMA] [Entered: 12/15/2022 10:00 AM] (120)
Menu
This website is using cookies.
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn more
x